Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout ; volume:22 ; number:1 ; day:7 ; month:4 ; year:2022 ; pages:1-11 ; date:12.2022
BMC medical informatics and decision making ; 22, Heft 1 (7.4.2022), 1-11, 12.2022
- Creator
-
Kampe, Ritch te
Boonen, Annelies
Jansen, Tim L.
Elling, Jan Mathis
Flendrie, Marcel
Eijk-Hustings, Yvonne van
Janssen, Matthijs
Durme, Caroline van
Vries, Hein de
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12911-022-01833-6
- URN
-
urn:nbn:de:101:1-2022062508471290503106
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kampe, Ritch te
- Boonen, Annelies
- Jansen, Tim L.
- Elling, Jan Mathis
- Flendrie, Marcel
- Eijk-Hustings, Yvonne van
- Janssen, Matthijs
- Durme, Caroline van
- Vries, Hein de
- SpringerLink (Online service)
Other Objects (12)
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study